{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:36:05Z","timestamp":1791408965616,"version":"4.3.3"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.canlet.2011.06.005","type":"journal-article","created":{"date-parts":[[2011,7,22]],"date-time":"2011-07-22T23:23:43Z","timestamp":1311377023000},"page":"20-28","source":"Crossref","is-referenced-by-count":28,"title":["Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors"],"prefix":"10.1016","volume":"311","author":[{"given":"Shikha","family":"Gaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Un","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2011.06.005_b0005","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.06.005_b0010","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1535-6108(03)00308-8","article-title":"p21Waf1\/Cip1 as a therapeutic target in breast and other cancers","volume":"4","author":"Weiss","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2011.06.005_b0015","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0304-3835(02)00495-0","article-title":"Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21(Waf1\/Cip1)","volume":"189","author":"Weiss","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.canlet.2011.06.005_b0020","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/381080a0","article-title":"Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I","volume":"381","author":"Rossi","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.06.005_b0025","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1124\/mol.104.004416","article-title":"Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha","volume":"67","author":"Hasinoff","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.canlet.2011.06.005_b0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0014-4827(89)90067-0","article-title":"Human autoantibody to topoisomerase II","volume":"180","author":"Hoffmann","year":"1989","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0035","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/oxfordjournals.annonc.a059316","volume":"6","author":"Hoffmann","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canlet.2011.06.005_b0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/bcr927","article-title":"New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists","volume":"6","author":"Carraway","year":"2004","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/modpathol.3880094","article-title":"Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables","volume":"13","author":"Depowski","year":"2000","journal-title":"Mod Pathol"},{"key":"10.1016\/j.canlet.2011.06.005_b0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/bcr985","article-title":"Determining sensitivity to rapamycin and its analogues in breast cancer patients","volume":"7","author":"Witton","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.270.5233.50","article-title":"PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints","volume":"270","author":"Keith","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.canlet.2011.06.005_b0060","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/85798","article-title":"DNA double-strand breaks: signaling, repair and the cancer connection","volume":"27","author":"Khanna","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.canlet.2011.06.005_b0065","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2011.06.005_b0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.molmed.2005.06.007","article-title":"An expanding role for mTOR in cancer","volume":"11","author":"Guertin","year":"2005","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.canlet.2011.06.005_b0075","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2011.06.005_b0080","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.1158\/0008-5472.CAN-05-0921","article-title":"a molecular target in squamous cell carcinomas of the head and neck","volume":"65","author":"Amornphimoltham","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0085","doi-asserted-by":"crossref","unstructured":"Y.M. Liao, C. Kim, and Y. Yen, Mammalian target of rapamycin and head and neck squamous cell carcinoma, Head Neck Oncol 3 22.","DOI":"10.1186\/1758-3284-3-22"},{"key":"10.1016\/j.canlet.2011.06.005_b0090","doi-asserted-by":"crossref","unstructured":"C. Clark, S. Shah, L. Herman-Ferdinandez, O. Ekshyyan, F. Abreo, X. Rong, J. McLarty, A. Lurie, E.J. Milligan, and C.O. Nathan, Teasing out the best molecular marker in the AKT\/mTOR pathway in head and neck squamous cell cancer patients, Laryngoscope 120, 1159\u201365.","DOI":"10.1002\/lary.20917"},{"key":"10.1016\/j.canlet.2011.06.005_b0095","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/0008-5472.CAN-06-2449","article-title":"Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer","volume":"67","author":"Nathan","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0100","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.06.005_b0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00063030-200923020-00002","article-title":"Current status and challenges associated with targeting mTOR for cancer therapy","volume":"23","author":"Dowling","year":"2009","journal-title":"BioDrugs"},{"key":"10.1016\/j.canlet.2011.06.005_b0110","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cell.2004.12.040","article-title":"The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation","volume":"120","author":"Beuvink","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2011.06.005_b0115","first-page":"5956","article-title":"Combined modalities of resistance in etoposide-resistant human KB cell lines","volume":"48","author":"Ferguson","year":"1988","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0120","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0006-2952(97)00614-X","article-title":"Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line","volume":"55","author":"Gaj","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.canlet.2011.06.005_b0125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/adt.2004.2.363","article-title":"Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays","volume":"2","author":"Solly","year":"2004","journal-title":"Assay Drug Dev Technol"},{"key":"10.1016\/j.canlet.2011.06.005_b0130","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1210\/en.2002-220830","article-title":"Interaction of the growth hormone receptor with cytokine-induced Src homology domain 2 protein in rat adipocytes","volume":"144","author":"Du","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.canlet.2011.06.005_b0135","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","article-title":"Analysis of apoptosis by propidium iodide staining and flow cytometry","volume":"1","author":"Riccardi","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1016\/j.canlet.2011.06.005_b0140","first-page":"886","article-title":"Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells","volume":"59","author":"Hosoi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0145","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1054\/drup.2002.0227","article-title":"Mechanisms of resistance to rapamycins","volume":"4","author":"Huang","year":"2001","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.canlet.2011.06.005_b0150","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1023\/A:1013167315885","article-title":"Resistance to rapamyc","volume":"20","author":"Huang","year":"2001","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.canlet.2011.06.005_b0155","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc1362","article-title":"The TOR pathway: a target for cancer therapy","volume":"4","author":"Bjornsti","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.canlet.2011.06.005_b0160","doi-asserted-by":"crossref","first-page":"42462","DOI":"10.1074\/jbc.C100466200","article-title":"ATM phosphorylates histone H2AX in response to DNA double-strand breaks","volume":"276","author":"Burma","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canlet.2011.06.005_b0165","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0955-0674(00)00201-5","article-title":"DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?","volume":"13","author":"Durocher","year":"2001","journal-title":"Curr Opin Cell Biol"},{"issue":"Pt 10","key":"10.1016\/j.canlet.2011.06.005_b0170","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1242\/jcs.113.10.1727","article-title":"The G(2) DNA damage checkpoint targets both Wee1 and cdc25","volume":"113","author":"Raleigh","year":"2000","journal-title":"J Cell Sci"},{"key":"10.1016\/j.canlet.2011.06.005_b0175","doi-asserted-by":"crossref","first-page":"22932","DOI":"10.1074\/jbc.274.33.22932","volume":"274","author":"Boulares","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canlet.2011.06.005_b0180","first-page":"3495","article-title":"Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis","volume":"58","author":"Smulson","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0185","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1476-4598-4-25","article-title":"Overcoming cisplatin resistance by mTOR inhibitor in lung cancer","volume":"4","author":"Wu","year":"2005","journal-title":"Mol Cancer"},{"key":"10.1016\/j.canlet.2011.06.005_b0190","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1158\/1078-0432.CCR-04-0361","article-title":"Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells","volume":"10","author":"Mondesire","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0195","first-page":"6141","article-title":"Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells","volume":"62","author":"Grunwald","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0200","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2008.03.024","article-title":"Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma","volume":"49","author":"Piguet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.canlet.2011.06.005_b0205","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1158\/1078-0432.CCR-05-0978","article-title":"Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival","volume":"12","author":"Tinari","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.canlet.2011.06.005_b0210","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canlet.2011.06.005_b0215","doi-asserted-by":"crossref","first-page":"R229","DOI":"10.1016\/S0960-9822(01)00112-9","article-title":"DNA repair: spot(light)s on chromatin","volume":"11","author":"Modesti","year":"2001","journal-title":"Curr Biol"},{"key":"10.1016\/j.canlet.2011.06.005_b0220","doi-asserted-by":"crossref","first-page":"18715","DOI":"10.1074\/jbc.274.26.18715","article-title":"Histone H1 dephosphorylation is mediated through a radiation-induced signal transduction pathway dependent on ATM","volume":"274","author":"Guo","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.canlet.2011.06.005_b0225","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.canlet.2011.06.005_b0230","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/sj.onc.1209992","article-title":"Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells","volume":"26","author":"Iwamaru","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.06.005_b0235","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1158\/1078-0432.CCR-06-0011","article-title":"A matter of life or death (or both): understanding autophagy in cancer","volume":"12","author":"Hait","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511003417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511003417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,28]],"date-time":"2021-11-28T15:00:16Z","timestamp":1638111616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383511003417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0304383511003417"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2011.06.005","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}